MyLife Technologies secures new growth capital

A consortium of informal investors has invested 0.5 million € in MyLife Technologies, a med tech company developing dermal delivery solutions based on its platform technology of ceramic nano-porous MicroNeedle Arrays (npMNA). MyLife Technologies will use this investment to accelerate the development of pharmaceutical applications of its npMNA technology.

The company focuses on applications in the field of prophylactic vaccines, therapeutic vaccines and specific small molecules. The npMNAs are made of biocompatible ceramic material and are combined with a dermal patch, allowing easy self-application by the patient. The nanopores of the MNA devices are used for storage of pharmaceutical compounds. This minimally invasive application method is pain-free and is an effective way to overcome the stratum corneum, the skin’s main barrier.

MyLife Technologies is a spin-off from University of Twente, MESA+, Institute for Nanotechnology, The Netherlands. In June 2015, the company opened its own lab in the  facilities of BioPartner Center at Leiden Bio Science Park. Technology patents have been obtained in Europe, USA, Japan and China.

CEO Pieter Jan Vos is very pleased: “This new capital is an important milestone for MyLife Technologies. It allows us to expand our lab facilities and our team. We will intensify and expand our development pipeline”.

Source: MyLife Technologies